All In Biotech

Free tool

FAERS Monitor: Nubeqa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

Reports naming NDA 212099 or its brand name (Nubeqa, Darolutamide). Reports on generic versions are filed under their own applications.

Reports

5,923

Serious

4,112

69% of reports

Hospitalization

1,300

Death reported

708

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

Nothing to show.

Reports by year received

View as table
YearReports
201934
2020152
2021204
2022316
2023722
20241,405
20251,987
20261,103

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,236 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.